ARCA Biopharma is a late-stage biopharmaceutical company based in Broomfield, CO, specializing in tailored healthcare and pharmacogenetic precision medicine for cardiovascular disease. They focus on developing safe and effective drug therapies for atrial fibrillation, a prevalent cardiovascular condition with unmet medical needs, particularly in patients with heart failure and left ventricular ejection fraction (LVEF) below 40.
Their flagship product, Gencaro, is potentially the first genetically-targeted treatment for atrial fibrillation, designed to address the individual responses of patients with a specific genotype that responds most favorably to the drug. With a mission to improve patient outcomes and revolutionize cardiovascular care, ARCA Biopharma conducts clinical trials and collaborates with researchers and investors to advance precision medicine in the field of cardiovascular disease.
Generated from the website